55 The landscape of prostate cancer management is evolving, with groundbreaking advancements in imaging technology playing a pivotal role. Prostate cancer, the second most common malignancy in men, often leads to bone metastases in advanced stages, significantly impacting morbidity and mortality rates. The importance of accurate detection methods for bone metastases has grown as clinicians strive to improve patient outcomes and tailor treatments effectively. The findings were published in the journal Seminars in Nuclear Medicine. Traditional methods such as CT scans and MRI, while valuable, face limitations. CT scans often miss early bone changes, as they primarily detect cortical destruction. MRI, although more sensitive to bone marrow involvement, requires lengthy examination times and often fails to cover the entire skeletal system comprehensively. These challenges have driven the development of advanced molecular imaging modalities. Bone scintigraphy, a cost-effective and widely available tool, has long been used to detect bone metastases. However, its low specificity frequently results in false positives. Single-photon emission computed tomography (SPECT) combined with CT (SPECT/CT) has enhanced diagnostic accuracy, providing better anatomical localisation and improved differentiation between benign and malignant lesions. Yet, SPECT/CT falls short compared to emerging techniques, particularly in lesion-based sensitivity. Positron emission tomography (PET) imaging is now heralded as a game-changer. Using radiopharmaceuticals such as fluorine-18 and gallium-68, PET scans offer unparalleled sensitivity and specificity. Radiotracers like 68Ga-PSMA and 18F-NaF target specific cancer characteristics or bone changes, enabling precise identification of metastatic sites. PET imaging not only detects soft tissue and skeletal metastases but also demonstrates a lower rate of false positives, reducing unnecessary follow-ups. Another transformative development is the integration of artificial intelligence (AI) and radiomics into imaging. These technologies streamline diagnosis by reducing interobserver variability, enhancing accuracy, and optimising workflow efficiency. AI-driven algorithms, for instance, can automate processes such as Bone Scan Index calculations, which were previously labour-intensive. Radiomics further complements PET imaging by extracting intricate data patterns, improving predictive insights, and aiding personalised treatment plans. Despite these advancements, accessibility remains a hurdle. PET imaging, while revolutionary, is not universally available due to high costs and the need for specialised infrastructure. For regions with limited resources, SPECT/CT continues to serve as a reliable alternative, although its limitations highlight the need for broader adoption of PET technologies. As imaging technologies advance, they are reshaping prostate cancer care. The shift towards more sensitive and specific tools is poised to enhance early detection, minimise diagnostic uncertainty, and ultimately improve survival rates. These innovations underscore the critical role of research and investment in the fight against cancer, paving the way for a future where precision diagnostics are universally accessible.